These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 14684475)
1. In vivo characterization of changes in glycine levels induced by GlyT1 inhibitors. Johnson KW; Clemens-Smith A; Nomikos G; Davis R; Phebus L; Shannon H; Love P; Perry K; Katner J; Bymaster F; Yu H; Hoffman BJ Ann N Y Acad Sci; 2003 Nov; 1003():412-4. PubMed ID: 14684475 [No Abstract] [Full Text] [Related]
2. The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Harsing LG; Gacsalyi I; Szabo G; Schmidt E; Sziray N; Sebban C; Tesolin-Decros B; Matyus P; Egyed A; Spedding M; Levay G Pharmacol Biochem Behav; 2003 Mar; 74(4):811-25. PubMed ID: 12667895 [TBL] [Abstract][Full Text] [Related]
3. ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Atkinson BN; Bell SC; De Vivo M; Kowalski LR; Lechner SM; Ognyanov VI; Tham CS; Tsai C; Jia J; Ashton D; Klitenick MA Mol Pharmacol; 2001 Dec; 60(6):1414-20. PubMed ID: 11723250 [TBL] [Abstract][Full Text] [Related]
4. Pharmacology and expression analysis of glycine transporter GlyT1 with [3H]-(N-[3-(4'-fluorophenyl)-3-(4'phenylphenoxy)propyl])sarcosine. Mallorga PJ; Williams JB; Jacobson M; Marques R; Chaudhary A; Conn PJ; Pettibone DJ; Sur C Neuropharmacology; 2003 Oct; 45(5):585-93. PubMed ID: 12941372 [TBL] [Abstract][Full Text] [Related]
5. [3H]-(R)-NPTS, a radioligand for the type 1 glycine transporter. Lowe JA; Drozda SE; Fisher K; Strick C; Lebel L; Schmidt C; Hiller D; Zandi KS Bioorg Med Chem Lett; 2003 Apr; 13(7):1291-2. PubMed ID: 12657266 [TBL] [Abstract][Full Text] [Related]
6. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Perry KW; Falcone JF; Fell MJ; Ryder JW; Yu H; Love PL; Katner J; Gordon KD; Wade MR; Man T; Nomikos GG; Phebus LA; Cauvin AJ; Johnson KW; Jones CK; Hoffmann BJ; Sandusky GE; Walter MW; Porter WJ; Yang L; Merchant KM; Shannon HE; Svensson KA Neuropharmacology; 2008 Oct; 55(5):743-54. PubMed ID: 18602930 [TBL] [Abstract][Full Text] [Related]
7. The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. Kinney GG; Sur C; Burno M; Mallorga PJ; Williams JB; Figueroa DJ; Wittmann M; Lemaire W; Conn PJ J Neurosci; 2003 Aug; 23(20):7586-91. PubMed ID: 12930797 [TBL] [Abstract][Full Text] [Related]
8. N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Aubrey KR; Vandenberg RJ Br J Pharmacol; 2001 Dec; 134(7):1429-36. PubMed ID: 11724748 [TBL] [Abstract][Full Text] [Related]
9. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. Chen L; Muhlhauser M; Yang CR J Neurophysiol; 2003 Feb; 89(2):691-703. PubMed ID: 12574447 [TBL] [Abstract][Full Text] [Related]
10. Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. Martina M; Gorfinkel Y; Halman S; Lowe JA; Periyalwar P; Schmidt CJ; Bergeron R J Physiol; 2004 Jun; 557(Pt 2):489-500. PubMed ID: 15064326 [TBL] [Abstract][Full Text] [Related]
11. Modulation of striatal dopamine release by glycine transport inhibitors. Javitt DC; Hashim A; Sershen H Neuropsychopharmacology; 2005 Apr; 30(4):649-56. PubMed ID: 15688094 [TBL] [Abstract][Full Text] [Related]
12. Inhibitors of GlyT1 affect glycine transport via discrete binding sites. Mezler M; Hornberger W; Mueller R; Schmidt M; Amberg W; Braje W; Ochse M; Schoemaker H; Behl B Mol Pharmacol; 2008 Dec; 74(6):1705-15. PubMed ID: 18815213 [TBL] [Abstract][Full Text] [Related]
14. GlyT1 - Up from the Ashes. The importance of not condemning a mechanism based on a single chemotype. Lindsley C ACS Chem Neurosci; 2010 Mar; 1(3):165-6. PubMed ID: 22778822 [No Abstract] [Full Text] [Related]
16. The glycine transport inhibitor sarcosine is an inhibitory glycine receptor agonist. Zhang HX; Lyons-Warren A; Thio LL Neuropharmacology; 2009; 57(5-6):551-5. PubMed ID: 19619564 [TBL] [Abstract][Full Text] [Related]
17. Effects of endogenous agonists, glycine and D-serine, on in vivo specific binding of [11C]L-703,717, a PET radioligand for the glycine-binding site of NMDA receptors. Haradahira T; Okauchi T; Maeda J; Zhang MR; Nishikawa T; Konno R; Suzuki K; Suhara T Synapse; 2003 Nov; 50(2):130-6. PubMed ID: 12923815 [TBL] [Abstract][Full Text] [Related]
18. Transmembrane domains 1 and 3 of the glycine transporter GLYT1 contain structural determinants of N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)-propyl]sarcosine specificity. Núñez E; Martínez-Maza R; Geerlings A; Aragón C; López-Corcuera B Neuropharmacology; 2005 Nov; 49(6):922-34. PubMed ID: 16143353 [TBL] [Abstract][Full Text] [Related]
19. Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1). Manahan-Vaughan D; Wildförster V; Thomsen C Eur J Neurosci; 2008 Oct; 28(7):1342-50. PubMed ID: 18973561 [TBL] [Abstract][Full Text] [Related]